The Latest Breaking News from FDA

Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral Suspension, 10 mg/mL.

Walmart says it plans to remove synthetic dyes and 30 other food additives from its store brands sold in the United States by January 2027

Housing and VA departments attack ‘radical left’ despite law limiting political activities of government employees

As ever, be cautious about what you hear from the Department of Health and Human Services.

Bored Panda contacted four dermatologists and plastic surgeons to find out more about Kybella, the FDA-approved treatment that targets the stubborn "double chin."

The U.S. government is nearing a partial shutdown, with a range of effects on public services and the broader economy

Penny stocks are highly volatile, but some of them have the potential to deliver outsized returns.

Guess which conservative think tank supplied the "evidence" for this one...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or…

RFK Jr is conducting a review of mifepristone, citing a deeply flawed study. The move could be devastating for women

US class action lawsuit alleges company failed to warn about risks of using contraceptive injection Depo-Provera